NCT01928927View on ClinicalTrials.gov

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
HIV-1 Infection
Interventions
DRUG

Telmisartan

Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.

Trial Locations (12)

14642

University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester

27514

Unc Aids Crs (3201), Chapel Hill

37232

Vanderbilt Therapeutics CRS (3652), Nashville

44106

Case CRS (2501), Cleveland

45267

Univ. of Cincinnati CRS (2401), Cincinnati

63110

Washington U CRS (2101), St Louis

77030

Houston AIDS Research Team CRS (31473), Houston

80045

University of Colorado Hospital CRS (6101), Aurora

90035

UCLA CARE Center CRS (601), Los Angeles

98104

University of Washington AIDS CRS (1401), Seattle

02114

Massachusetts General Hospital ACTG CRS (101), Boston

00935

Puerto Rico-AIDS CRS (5401), San Juan

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT01928927 - Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) | Biotech Hunter | Biotech Hunter